Surgical revascularization remains the standard treatment for symptomatic moyamoya
disease (MMD). As with any major surgical treatment, revascularization is associated with …

Background The optimal antithrombotic (antiplatelet or anticoagulant) treatment of patients
undergoing extracranial carotid artery interventions is a subject of debate. The aim of this …

BACKGROUND: Short-term dual antiplatelet therapy (DAPT) reduces early stroke
recurrence after mild noncardioembolic ischemic stroke (NCIS). We aim to evaluate …

Antiplatelet therapy plays a crucial role in a number of cardiovascular disorders. We
currently have a range of antiplatelet agents in our armamentarium. In this review, we aim to …

Background: The CHANCE-2 study compared 3 weeks of aspirin–ticagrelor to aspirin–
clopidogrel in CYP2C19 loss-of-function (LOF) allele carriers following a transient ischemic …

Background The prevalence of ex vivo 'high on-treatment platelet reactivity (HTPR)'and its
relationship with recurrent vascular events/outcomes in patients with ischaemic …

Objective To investigate the safety and effectiveness of direct oral anticoagulants (DOAC)
versus vitamin K antagonists (VKA) after recent stroke in patients with atrial fibrillation (AF) …

Patients with acute ischemic stroke may present with minor neurologic deficits. Acute
treatment decisions depend on the disability imposed by the symptoms along with …

1.1. Purpose The European Society for Vascular Surgery (ESVS) has developed a series of
clinical practice guidelines for clinicians caring for patients with vascular diseases. This is …

Background and purpose Guidelines recommend that patients with high-risk TIAs and minor
strokes presenting within 1–3 days from onset should be offered dual antiplatelet therapy …